Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Yun, H M ^a   Oh, J H ^a   Shim, J H ^b   Ban, J O ^a   Park, K R ^a   Kim, J H ^c   Lee, D H ^c   Kang, J W ^c   Park, Y H ^d   Yu, D ^d   Kim, Y ^a   Han, S B ^a   Yoon, D Y ^c   Hong, J T ^a  

^a Chungbuk National University   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Konkuk University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

IL 32 ; Lymphocytes; NF B; STAT3; Tumor growth

Indexed keywords

CASPASE 3; CASPASE 9; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 32BETA; INTERLEUKIN 6; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL GROWTH; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; INOCULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; TRANSGENIC MOUSE; TUMOR GROWTH; UPREGULATION;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FEMALE; HCT116 CELLS; HUMANS; INTERLEUKINS; KI-67 ANTIGEN; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; NF-KAPPA B; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS;

MUS; MUS MUSCULUS;

EID: 84879359529     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.166     Document Type: Article

References (56)

1. Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010; 29: 3313-3323.
2. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612.
3. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
4. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20: 198-208.
5. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y et al. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci USA 2009; 106: 16369-16374.
6. Huber NL, Bailey SR, Schuster R, Ogle CK, Lentsch AB, Pritts TA. Prior thermal injury accelerates endotoxin-induced inflammatory cytokine production and intestinal nuclear factor-kappaB activation in mice. J Burn Care Res 2012; 33: 279-285.
7. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-584.
8. Sondergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8 + T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 2007; 56: 1417-1428.
9. Song JK, Park MH, Choi DY, Yoo HS, Han SB, Yoon do Y et al. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 2012; 7: e33747.
10. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y et al. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64: 1152-1156.
11. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-310.
12. Muerkoster S, Arlt A, Sipos B, Witt M, Grossmann M, Kloppel G et al. Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 2005; 65: 1316-1324.
13. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004; 6: 390-400.
14. Arlt A, Schafer H. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002; 40: 336-347.
15. Xu Y, Josson S, Fang F, Oberley TD St, Clair DK, Wan XS et al. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 2009; 69: 3267-3271.
16. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274: 31868-31874.
17. Sakamoto K, Hikiba Y, Nakagawa H, Hayakawa Y, Yanai A, Akanuma M et al. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology 2010; 139: 226-238 e226.
18. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
19. Kim G, Khanal P, Lim SC, Yun HJ, Ahn SG, Ki SH et al. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. Carcinogenesis 2012; 34: 341-350.
20. Hyun YS, Han DS, Lee AR, Eun CS, Youn J, Kim HY. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 2012; 33: 931-936.
21. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
22. Malamut G, El Machhour R, Montcuquet N, Martin-Lanneree S, Dusanter-Fourt I, Verkarre V et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010; 120: 2131-2143.
23. Malamut G, El Machhour R, Montcuquet N, Martin-Lanneree S, Dusanter-Fourt I, Verkarre V et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 120: 2131-2143.
24. Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007; 67: 8494-8503.
25. Cheon S, Lee JH, Park S, Bang SI, Lee WJ, Yoon DY et al. Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. J Biol Chem 2011; 286: 12049-12055.
26. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG et al. 'Re-educating' tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205: 1261-1268.
27. Gerondakis S, Strasser A, Metcalf D, Grigoriadis G, Scheerlinck JY, Grumont RJ. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 1996; 93: 3405-3409.
28. Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS et al. A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 2009; 128(1 Suppl): e532-e540.
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
30. van Diest PJ, Brugal G, Baak JP. Proliferation markers in tumours: interpretation and clinical value. J Clin Pathol 1998; 51: 716-724.
31. Matthews GM, Newbold A, Johnstone RW. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res 2012; 116: 165-197.
32. Keating J, Tsoli M, Hallahan AR, Ingram WJ, Haber M, Ziegler DS. Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma. Mol Cancer Ther 2012; 11: 2654-2663.
33. Myoung H, Kim MJ, Lee JH, Ok YJ, Paeng JY, Yun PY. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006; 35: 1005-1010.
34. Figueroa A, Correnti M, Avila M, Andea A, DeVilliers P, Rivera H. Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type? Otolaryngol Head Neck Surg 2010; 142: 179-183.
35. Pontes HA, Pontes FS, Silva BS, Cury SE, Fonseca FP, Salim RA et al. Immunoexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in a case of ameloblastic fibrosarcoma. Ann Diagn Pathol 2010; 14: 447-452.
36. Bologna-Molina R, Mosqueda-Taylor A, Molina-Frechero N, Mori-Estevez AD, Sanchez-Acuna G. Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. Med Oral Patol Oral Cir Bucal 18: e174-e179.
37. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005; 22: 131-142.
38. Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES et al. IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene 2011; 30: 3345-3359.
39. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006; 25: 333-356.
40. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today 2000; 21: 420-422.
41. Wang KF, Ye SL, Song LJ, Weng YQ. The metastasis of hepatocarcinoma can be inhibited by T lymphocytes reconstitution in nude mice model. Hepatogastroenterology 2010; 57: 1220-1226.
42. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
43. Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A. Molecular chemotherapy and chemotherapy: a new front against late stage hormone refractory prostate cancer. Clin Cancer Res 2011; 17: 4006-4018.
44. Holland AM, Zakrzewski JL, Tsai JJ, Hanash AM, Dudakov JA, Smith OM et al. Extrathymic development of murine T cells after bone marrow transplantation. J Clin Invest 2012; 122: 4716-4726.
45. Kennedy RL, Darne J, Davies R, Price A. Thyrotoxicosis and hyperemesis gravidarum associated with a serum activity which stimulates human thyroid cells in vitro. Clin Endocrinol (Oxf) 1992; 36: 83-89.
46. Cheng WH, Holmstrom A, Li X, Wu RT, Zeng H, Xiao Z. Effect of dietary selenium and cancer cell xenograft on peripheral T and B lymphocytes in adult nude mice. Biol Trace Elem Res 2012; 146: 230-235.
47. Romano R, Palamaro L, Fusco A, Iannace L, Maio S, Vigliano I et al. From murine to human nude/SCID: the thymus, T-cell development and the missing link. Clin Dev Immunol 2012; 2012: 467101.
48. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
49. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
50. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 2009; 69: 2497-2505.
51. El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, Lhocine N et al. General nature of the STAT3-activated anti-inflammatory response. J Immunol 2006; 177: 7880-7888.
52. Suzuki K, Nakazato H, Matsui H, Hasumi M, Shibata Y, Ito K et al. NK cell-mediated antitumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 2001; 69: 531-537.
53. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
54. Hou T, Ray S, Lee C, Brasier AR. The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem 2008; 283: 30725-30734.
55. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-1577.
56. Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S et al. Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA. Hybridoma (Larchmt) 2010; 29: 501-509.